JUBLPHARMA — Jubilant Pharmova Share News
0.000.00%
- IN₹152.72bn
- IN₹174.03bn
- IN₹82.80bn
Brief: India's Jubilant Pharmova March-Quarter Consol Net Profit Falls
Brief: Jubilant Pharmova Completes Safety Studies For Novel Oral Formulation Of Remdesivir
India bans exports of Remdesivir drug as new COVID-19 cases hit another record (updated)
Brief: Jubilant Pharmova Says Arvind Chokhany Named Group CFO
Brief: India's Jubilant Life Sciences Dec-Qtr Consol Net Profit Rises
Issued Commercial Papers Of 900 Million Rupees
Brief: Jubilant Life Sciences Says Unit Enters Strategic Partnership With Sofie Biosciences
Brief: Jubilant Life Sciences To Issue Non-Convertible Debentures Of Up To 1 Bln Rupees
Brief: Jubilant Life Posts Lower Profit, Says Increased Remdesivir Output Capacity
Brief: Jubilant Life Sciences Issues Commercial Papers Of 300 Mln Rupees
India's Jubilant Life Sciences eyes worst day in 5 months as Q1 profit slumps
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
India's shortage of remdesivir is easing, says producer Cipla
Brief: Navidea Signs Binding Framework For Commercialization Partnership With Jubilant Radiopharma
Brief: Jubilant Life Sciences Launches Remdesivir For Injection Under Brand Name 'JUBI-R'
India's Cipla prices its generic remdesivir at $53.34 per vial, below rivals (updated)
India's Cipla set to undercut rivals with generic remdesivir -sources
Mylan prices its generic remdesivir in India at $64 per 100 mg vial (updated)
Mylan to launch generic remdesivir version in India at $64 per 100 mg vial